Technologies
This technology is a method for detecting and treating immune-related adverse events such as autoimmune hemolytic anemia (AIHA).
Autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by immune-mediated destruction of red blood cells and can arise as a complication of immune checkpoint inhibitor therapy. Diagnosis and management are challenging due to heterogeneous clinical presentation and a lack of reliable predictive biomarkers. Current treatments rely on broad immunosuppression, which can cause significant side effects and fail to address underlying disease mechanisms. Therapies and predictive tools that enable earlier detection and address the root immunological cause of AIHA are poised to provide better options for patients afflicted with AIHA.
This technology is a dual diagnostic and therapeutic approach for AIHA that identifies disease-associated T-cell populations in patient blood samples, including CD4+CD39+ cells, as predictive biomarkers. This technology also targets these pathogenic T cells subsets by degrading extracellular ATP, reducing CD39 positive T cells lacking CD73, FoxP3 and CD25, which are implicated in AIHA and immune-related adverse events. By addressing these underlying immunological mechanisms, this technology enables both early detection and targeted treatment of AIHA.
This technology has been validated in murine models where expansion of CD39+ T cell populations correlates with AIHA, with similar populations observed in human samples.
Patent Pending
IR CU24097
Licensing Contact: Jerry Kokoshka